Abstract
Purpose :
The objective of this study is too determine the quantitative changes in the electrophysiologic amplitudes and latencies from baseline to month 12 in ranibizumab-treated eyes with exudative AMD (age related macular degeneration).
Methods :
This is an open label study assessing ERG (electroretinogram) and EOG (electrooculogram) outcomes in patients with exudative AMD. ERG and EOG testing were conducted at baseline, and at 6 and 12 months after initiating ranibizumab treatment. Ten patients with exudative AMD were enrolled and received monthly intravitrous ranibizumab injections.
Results :
No statistically significant differences were identified in ERG or EOG testing including: single photopic flash, maximal photopic response, rod response, 30 Hz flicker, notation of oscillatory potentials, multifocal ERG, EOG testing.
Conclusions :
Monthly intravitreous injection of ranibizumab for treatment of exudative AMD did not demonstrate statistically significant ERG or EOG changes over the course of 1 year treatment.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.